| Literature DB >> 33511286 |
Himali Meshram1, Shilpa Velhal2, Varsha Padwal2, Jyoti Sutar2, Ravi Kadam2, Jacinta Pereira2, Gauri Bhonde3, Kalyani Karandikar3, Vikrant Bhor3, Vainav Patel3, Naman S Shetty1, Ira Shah1.
Abstract
AIM OF THE STUDY: To determine the hepatic interferon γ (IFN-γ) and tumor necrosis factor α (TNF-α) levels in infants with neonatal cholestasis (NC) and associated cytomegalovirus (CMV) infection.Entities:
Keywords: CMV; immunochemistry; neonatal cholestasis
Year: 2020 PMID: 33511286 PMCID: PMC7816637 DOI: 10.5114/ceh.2020.102172
Source DB: PubMed Journal: Clin Exp Hepatol ISSN: 2392-1099
Details of each patient
| CMV IgM positive | CMV IgG positive | Blood CMV PCR positive | Liver CMV PCR positive | IFN-γ levels | TNFα levels | |
|---|---|---|---|---|---|---|
| Patient 1 | Yes | No | Yes | Yes | 2 | 2 |
| Patient 2 | No | Yes | Yes | Yes | – | – |
| Patient 3 | Yes | Yes | Yes | Yes | 2 | 0.2 |
| Patient 4 | No | Yes | Yes | Yes | 0.8 | 2.6 |
| Patient 5 | No | Yes | Yes | No | 2 | 1 |
| Patient 6 | No | Yes | Yes | Yes | 2 | 1.2 |
| Patient 7 | No | Yes | Yes | Yes | 1.8 | 2 |
| Patient 8 | No | No | Yes | Yes | 2 | – |
| Patient 9 | Yes | Yes | Yes | Yes | 1.8 | 2 |
| Patient 10 | Yes | No | Yes | Yes | 2 | 1.6 |
| Patient 11 | No | No | Yes | Yes | 1.6 | 2 |
| Patient 12 | No | No | Yes | Yes | 2 | 1 |
| Patient 13 | No | Yes | No | Yes | 1.8 | 1 |
| Patient 14 | No | No | Yes | Yes | 1.4 | 1.4 |
| Patient 15 | No | Yes | Yes | Yes | 1.8 | 1.2 |
| Patient 16 | No | Yes | Yes | Yes | 2 | 2 |
| Patient 17 | No | Yes | Yes | Yes | 2 | 1.8 |
| Patient 18 | No | Yes | Yes | Yes | 0.4 | 1 |
| Patient 19 | Yes | Yes | Yes | No | 1 | 1.4 |
| Patient 20 | Yes | No | No | No | 1.8 | 2 |
| Patient 21 | No | Yes | Yes | Yes | 2 | 2 |
CMV – cytomegalovirus, IgG – immunoglobulin G, IgM – immunoglobulin M, IFN-γ – interferon γ, TNF-α – tumor necrosis factor α
Factors associated with levels of tumor necrosis factor α (TNF-α) and interferon γ (IFN-γ)
| TNFα | Positive + high positive ( | Low positive ( | |
|---|---|---|---|
| Age (months) | 3.1 ±1.9 | 2.3 ±1.2 | 1 |
| Bilirubin (mg/dl) | 11 ±7 | 11.1 ±5.3 | 1.1 |
| SGOT (IU/l) | 237.8 ±158 | 251.8 ±150 | 0.557 |
| SGPT (IU/l) | 147.9 ±126.2 | 203.8 ±206 | 0.0033 |
| Age (months) | 3.1 ±1.9 | 2.3 ±1.2 | 1 |
| Bilirubin (mg/dl) | 11.9 ±6.3 | 8.6 ±3.9 | 0.667 |
| SGOT (IU/l) | 268.9 ±144.2 | 131.8 ±111.2 | 0 |
| SGPT (IU/l) | 164.2 ±163.4 | 188.8 ±188.6 | 0.201 |
SGOT – serum glutamic oxaloacetic transaminase, SGPT – serum glutamate pyruvate transaminase
Factors associated with positive and low positive levels of tumor necrosis factor α (TNF-α)
| TNFα | Positive + high positive ( | Low positive ( | |
|---|---|---|---|
| Gender | |||
| Male | 5 (50%) | 5 (55.5%) | 1 |
| Female | 5 (50%) | 4 (44.4%) | |
| Liver CMV PCR positive | 9 (90%) | 7 (77.7%) | 0.582 |
| Blood CMV PCR positive | 9 (90%) | 8 (88.8%) | 1 |
| CMV IgM positive | 4 (40%) | 2 (22.2%) | 0.628 |
| CMV IgG positive | 6(60%) | 7 (77.7%) | 0.628 |
| Diagnosis | |||
| Biliary atresia | 6 (60%) | 2 (22.2%) | 0.1698 |
| Neonatal hepatitis | 4 (40%) | 7 (77.7%) | |
| Outcome | |||
| Recovered | 5 (50%) | 4 (44.4) | 0.8363 |
| Chronic liver disease | 2 (20%) | 1 (11.1%) | |
| On follow-up | 1 (10%) | 1 (11.1%) | |
| Lost to follow-up | 2 (20%) | 3 (33.3%) |
CMV – cytomegalovirus, IgG – immunoglobulin G, IgM – immunoglobulin M
Factors associated with positive and low positive levels of interferon γ (IFN-γ)
| IFN-γ | Positive ( | Low positive + negative ( | |
|---|---|---|---|
| Gender | |||
| Male | 9 (56.25%) | 2 (50%) | 1 |
| Female | 7 (43.75%) | 2 (50%) | |
| Liver CMV PCR positive | 14 (87.5%) | 3 (75%) | 0.5088 |
| Blood CMV PCR positive | 14 (87.5%) | 4 (100%) | 1 |
| CMV IgM positive | 5 (31.25%) | 1 (25%) | 1 |
| CMV IgG positive | 10 (62.5%) | 3 (75%) | 1 |
| Diagnosis | |||
| Biliary atresia | 6 (37.5%) | 2 (50%) | 1 |
| Neonatal hepatitis | 10 (62.5%) | 2 (50%) | |
| Outcome | |||
| Recovered | 7 (43.75%) | 2 (50%) | 0.6508 |
| Chronic liver disease | 3 (18.75%) | 0 (0%) | |
| On follow-up | 1 | 1 (25%) | |
| Lost to follow-up | 5 | 1 (25%) |
CMV – cytomegalovirus, IgG – immunoglobulin G, IgM – immunoglobulin M